Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences

Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences Influenza vaccine candidate OVX836 safety profile and efficacy signals from Phase 2a dose-optimization study to be presented at UIV 2022  Preclinical proof of cross-protection against SARS-COV-2 with OVX033 in hamster challenge model to be presented at Options XI Additional results on the …

Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine

Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine  Lyon, France – June 23, 2022 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has secured EUR 10M from Bpifrance to support the further clinical development of …

Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836

Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836 Excellent safety continues to be observed in ongoing Phase 2a dose optimization study (OVX836-003) Phase 2a dose optimization study extended to elderly population cohort (OVX836-003) Additional Phase 2a trial combining OVX836 with conventional quadrivalent influenza vaccine (QIV) initiated with first participants enrolled in Australia …

Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines

Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines Lyon, France – May 17, 2022 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research collaboration with the National Institute of Allergy and …

Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology

Data also discussed in context of OVX836 clinical development update presentation at 2022 World Vaccine Congress Lyon, France – April 21, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today that the Phase 2a results for its broad-spectrum influenza vaccine candidate, OVX836, have been published under the title “Randomized, …

Osivax Appoints Dr. Michael Watson, Former President of Moderna Vaccine Division, to its Board of Directors

Company also announces upcoming presentation of clinical data for its pan-influenza vaccine candidate at World Vaccine Congress  Lyon, France – April 14, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today the appointment of Dr. Michael Watson to its Board of Directors. Dr. Watson brings over 20 years …

Osivax Announces Promising Phase 2a Results with Universal Influenza Vaccine Candidate, OVX836, and Initiation of Additional Phase 2a Dose Optimization Study

Osivax Announces Promising Phase 2a Results with Universal Influenza Vaccine Candidate, OVX836, and Initiation of Additional Phase 2a Dose Optimization Study Phase 2a results demonstrate excellent safety profile alongside strong, dose-dependent immune response First patient enrolled in complementary Phase 2a dose optimization study Lyon, France – December 21st, 2021 – Osivax, a biopharmaceutical company focused …

Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases

Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases Encouraging safety and cellular immune response data as well as a promising reactogenicity profile warrant further evaluation of OVX836 in Phase 2a study Lyon, France – December 2nd, 2021 – Osivax, a biopharmaceutical company focused …

OSIVAX appoints Dr. W. Ripley Ballou (M.D) as member of its Clinical Advisory Board

Rip Ballou’s appointment will strengthen OSIVAX’s ambition to develop a pipeline of disruptive vaccines against infectious diseases. Lyon, France – September 22, 2021 – OSIVAX, a biopharmaceutical company focused on the development of “universal” vaccines against mutating viruses, including influenza and coronaviruses, announced today the appointment of Dr. Ripley Ballou (MD) as member of its Clinical …

Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate

Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Full immunogenicity and safety results expected for early 2021 –Lyon, France – September 10, 2020 –Osivax announced today that the Last Subject’s Last Visit (LSLV) occurred in the Phase 2a clinical trial of OVX836 universal Influenza …